Anabolic treatments for osteoporosis in postmenopausal women.
Anabolic treatments for osteoporosis in postmenopausal women.
复制标题
DOI：
10.12703/r/10-44
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Tobias JH
中科院分区：
文献类型：
--
作者：
Hassan N;Gregson CL;Tobias JH
通常推荐抗骨吸收药物作为绝经后妇女骨质疏松症的一线治疗。这些药物抑制骨吸收但不重建骨，从而限制了它们的疗效。由于担心罕见的副作用，包括非典型股骨骨折和颌骨坏死，抗骨吸收药物的使用进一步受到阻碍。合成代谢治疗通过刺激新骨形成克服抗骨吸收治疗的局限性，从而更有效地降低骨折风险。本综述总结了目前可用于治疗绝经后女性骨质疏松症的三种合成代谢药物：特立帕肽、阿巴洛帕肽和罗莫索单抗的最新试验数据。回顾了比较合成代谢和抗吸收治疗的头对头研究的数据。目前，合成代谢治疗通常只用于骨折风险极高的严重骨质疏松症患者；讨论了限制其更广泛使用的因素以及未来可能如何改变。
Antiresorptive agents are generally recommended as first-line treatment for osteoporosis in postmenopausal women. These drugs suppress bone resorption but do not rebuild bone, limiting their efficacy. Antiresorptive use is further hampered by concerns over rare side effects, including atypical femoral fractures and osteonecrosis of the jaw. Anabolic treatments overcome limitations of antiresorptive treatment by stimulating new bone formation, reducing the risk of fracture with greater efficacy. This review summarises the latest trial data for the three anabolic agents currently available for the treatment of osteoporosis in postmenopausal women: teriparatide, abaloparatide, and romosozumab. Data from head-to-head studies comparing anabolic and antiresorptive treatments are reviewed. At present, anabolic treatments are generally reserved for use in patients with severe osteoporosis at very high fracture risk; the factors limiting their more widespread use are discussed together with how this may change in the future.